2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Wednesday, October 24, 2018

11:00AM-12:30PM: Abstract Number: 2979

Innovative Approaches for the Assessment of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Ultrasound Evaluation of Pleural Irregularities and Semiquantitative and Quantitative Analysis of Lung CT

6W022 ACR Abstract: Muscle Biology, Myositis & Myopathies II: Clinical & Misc Topics (2976–2981)

11:00AM-12:30PM: Abstract Number: 2977

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Reduces T-Cell Population and Downregulates Type 1 and 2 Interferon Activities in Lesional Dermatomyositis Skin

6W022 ACR Abstract: Muscle Biology, Myositis & Myopathies II: Clinical & Misc Topics (2976–2981)

11:00AM-12:30PM: Abstract Number: 2984

Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)

6W023 ACR Abstract: RA–DX, Manifestations, & Outcomes VI: Outcomes Reports (2982–2987)

11:00AM-12:30PM: Abstract Number: 2974

Long-Term Survival in Lung Transplantation for Interstitial Lung Disease Due to Rheumatic Systemic Diseases. Study of 26 Cases of a Single Center

6W021 ACR Abstract: Misc Rheumatic & Inflam DZ II (2970–2975)

11:00AM-12:30PM: Abstract Number: 2952

Major NSAID Toxicity: Derivation and Internal Validation of a Simple Clinical Risk Score

6W018 ACR Abstract: Epidemiology & Pub Health IV: Determinants & Consequences of Tx (2952–2957)

11:00AM-12:30PM: Abstract Number: 2991

Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study

6W025 ACR Abstract: Vasculitis–Non-ANCA-Assocd & Rel D/Os III: Clinical Subtype & Outcome(2988–2993)

11:00AM-12:30PM: Abstract Number: 2981

Mitochondrial Extrusion and Autoimmunity in Juvenile Dermatomyositis

6W022 ACR Abstract: Muscle Biology, Myositis & Myopathies II: Clinical & Misc Topics (2976–2981)

11:00AM-12:30PM: Abstract Number: 2958

Multi-Site Study Evaluating Performance on Lupus Nephritis Quality Measures

6W019 ACR Abstract: Measures of Healthcare Quality II: QI in SLE, Gout & JIA (2958–2963)

11:00AM-12:30PM: Abstract Number: 2972

Multicentric Reticulohistiocytosis (1980-2017): A Rare Disease, Commonly Associated with Malignancy and Autoimmunity

6W021 ACR Abstract: Misc Rheumatic & Inflam DZ II (2970–2975)

11:00AM-12:30PM: Abstract Number: 2982

Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up

6W023 ACR Abstract: RA–DX, Manifestations, & Outcomes VI: Outcomes Reports (2982–2987)

11:00AM-12:30PM: Abstract Number: 2998

Opioid Use Among SLE Patients and Controls in the Population-Based Michigan Lupus Epidemiology & Surveillance (MILES) Cohort

6W027 ACR/ARHP Abstract: Health Services Research II: Economic & Clinical Implications (2994–2999)

11:00AM-12:30PM: Abstract Number: 2978

Performance of the 2017 European League Against Rheumatism / American College of Rheumatology (EULAR/ACR) Classification Criteria for Adult Idiopathic Inflammatory Myopathies (IIM) in an Australian Cohort

6W022 ACR Abstract: Muscle Biology, Myositis & Myopathies II: Clinical & Misc Topics (2976–2981)

11:00AM-12:30PM: Abstract Number: 2947

Peripheral Helper T Cells in Systemic Lupus Erythematosus

6W024 ACR Abstract: SLE–Etiology & Pathogenesis II (2946–2951)

11:00AM-12:30PM: Abstract Number: 2967

Potent Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Block Fructose-Induced Inflammation Via Increase in AMP Kinase Activity

6W020 ACR Abstract: Metabolic & Crystal Arthropathies–Basic Science & Imaging (2964–2969)

11:00AM-12:30PM: Abstract Number: 2987

RAPID Remission during the First Year in EARLY ACTIVE Rheumatoid Arthritis Is Associated with Better 5 YEARS Structural Damage Outcomes

6W023 ACR Abstract: RA–DX, Manifestations, & Outcomes VI: Outcomes Reports (2982–2987)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].